ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years
Milad Ashrafizadeh
Matched on ORCID iD 0000-0001-6605-822X; OpenAlex author ID A5090838781. Sources: OpenAlex.
Their work
- Papers
- 10 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 16
2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 2 papers · 2024: 3 papers · 2025: 2 papers
Papers 10
- A novel BCAT1 inhibitor bufalin sensitizes pancreatic cancer cells to chemotherapy. Co-author DOI 10.1016/j.gendis.2024.101503↗
- Inflammation, microbiota, and pancreatic cancer. Co-author DOI 10.1186/s12935-025-03673-6↗
- Molecular profile of metastasis, cell plasticity and EMT in pancreatic cancer: a pre-clinical connection to aggressiveness and drug resistance. First author DOI 10.1007/s10555-023-10125-y↗
- SKP2 promotes the metastasis of pancreatic ductal adenocarcinoma by suppressing TRIM21-mediated PSPC1 degradation. Co-author DOI 10.1016/j.canlet.2024.216733↗
- Acquired and intrinsic gemcitabine resistance in pancreatic cancer therapy: Environmental factors, molecular profile and drug/nanotherapeutic approaches. Co-author DOI 10.1016/j.envres.2023.117443↗
- Cell membrane-camouflaged bufalin targets NOD2 and overcomes multidrug resistance in pancreatic cancer. Co-author DOI 10.1016/j.drup.2023.101005↗
- A bioinformatics analysis, pre-clinical and clinical conception of autophagy in pancreatic cancer: Complexity and simplicity in crosstalk. Co-author DOI 10.1016/j.phrs.2023.106822↗
- Long noncoding RNAs (lncRNAs) in pancreatic cancer progression. Co-author DOI 10.1016/j.drudis.2022.05.012↗
- Pre-Clinical and Clinical Applications of Small Interfering RNAs (siRNA) and Co-Delivery Systems for Pancreatic Cancer Therapy. Co-author DOI 10.3390/cells10123348↗
- Apigenin as Tumor Suppressor in Cancers: Biotherapeutic Activity, Nanodelivery, and Mechanisms With Emphasis on Pancreatic Cancer. Co-author DOI 10.3389/fchem.2020.00829↗
Closest collaborators
The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Xianbin Zhang · 6 shared papers, 2023–2025 · strength 1.36
- Paper Acquired and intrinsic gemcitabine resistance in pancreatic cancer therapy: Environmental factors, molecular profile an… DOI 10.1016/j.envres.2023.117443↗
- Paper Molecular profile of metastasis, cell plasticity and EMT in pancreatic cancer: a pre-clinical connection to aggressiven… DOI 10.1007/s10555-023-10125-y↗
- Paper A novel BCAT1 inhibitor bufalin sensitizes pancreatic cancer cells to chemotherapy. DOI 10.1016/j.gendis.2024.101503↗
- Peng Gong · 2 shared papers, 2024–2025 · strength 0.45
- Jiahui Yuan · 2 shared papers, 2023–2024 · strength 0.36
- Alan Prem Kumar · 2 shared papers, 2021–2022 · strength 0.31
- Xiaoliang Chen · 1 shared paper, 2025 · strength 0.27
- Dengfeng Wu · 1 shared paper, 2025 · strength 0.27
- Zhenli Guo · 1 shared paper, 2024 · strength 0.26
- Wei Zhang · 1 shared paper, 2025 · strength 0.25
- Pingping Zhang · 1 shared paper, 2024 · strength 0.21
- Yuzhuo Z. Wang · 1 shared paper, 2022 · strength 0.19
- Weiguang Li · 1 shared paper, 2023 · strength 0.15
- Peng Gong · 1 shared paper, 2023 · strength 0.15
- Wei Zhang · 1 shared paper, 2023 · strength 0.15
- Sepideh Mirzaei · 1 shared paper, 2021 · strength 0.12
- Kiavash Hushmandi · 1 shared paper, 2021 · strength 0.12
- Hamed Mirzaei · 1 shared paper, 2020 · strength 0.11
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.